Risk factor
High price volatility
Profitability factor
Greatly overvalued vs peers
In Guru Portfolios
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
| Steven Cohen | Point72 Asset Management, L.P. | 0.0% | +0.01% |
| Kenneth Griffin | CITADEL ADVISORS LLC | 0.0% | +0.00% |
About
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of KMTS is 29.2 and suggests 6.49% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio